Sarepta Therapeutics, Inc. (NASDAQ:SRPT)‘s stock had its “buy” rating reiterated by Oppenheimer Holdings, Inc. in a research note issued to investors on Thursday. They presently have a $76.00 price objective on the biotechnology company’s stock. Oppenheimer Holdings, Inc.’s price objective indicates a potential upside of 76.70% from the company’s previous close.

SRPT has been the topic of a number of other research reports. Vetr downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating and set a $36.86 price objective on the stock. in a research report on Monday, May 22nd. BidaskClub raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Credit Suisse Group set a $64.00 target price on shares of Sarepta Therapeutics and gave the company a “buy” rating in a report on Tuesday, July 18th. Nomura reaffirmed a “buy” rating and set a $84.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, May 23rd. Finally, Leerink Swann reaffirmed a “buy” rating and set a $60.00 target price (up from $52.00) on shares of Sarepta Therapeutics in a report on Tuesday, July 18th. Nine analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $62.31.

Shares of Sarepta Therapeutics (NASDAQ SRPT) opened at 43.01 on Thursday. Sarepta Therapeutics has a 52 week low of $25.47 and a 52 week high of $63.73. The stock’s 50 day moving average is $39.34 and its 200 day moving average is $34.16. The stock’s market cap is $2.77 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.92) by $0.46. The company had revenue of $35.01 million for the quarter, compared to the consensus estimate of $22.52 million. The firm’s revenue for the quarter was up 350000.0% on a year-over-year basis. During the same quarter last year, the company earned ($1.19) EPS. On average, equities analysts forecast that Sarepta Therapeutics will post ($1.23) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/09/09/sarepta-therapeutics-inc-srpt-rating-reiterated-by-oppenheimer-holdings-inc.html.

In related news, CEO Douglas S. Ingram bought 47,058 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The stock was bought at an average cost of $42.50 per share, with a total value of $1,999,965.00. Following the completion of the purchase, the chief executive officer now owns 382,058 shares of the company’s stock, valued at approximately $16,237,465. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Shamim Ruff sold 12,138 shares of the firm’s stock in a transaction on Friday, July 21st. The shares were sold at an average price of $42.97, for a total transaction of $521,569.86. Following the transaction, the senior vice president now directly owns 27,312 shares of the company’s stock, valued at $1,173,596.64. The disclosure for this sale can be found here. Insiders have sold 78,056 shares of company stock valued at $3,224,208 over the last ninety days. 9.60% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of SRPT. Russell Investments Group Ltd. grew its stake in Sarepta Therapeutics by 63.9% during the first quarter. Russell Investments Group Ltd. now owns 38,273 shares of the biotechnology company’s stock valued at $1,133,000 after acquiring an additional 14,919 shares in the last quarter. Wells Fargo & Company MN grew its stake in Sarepta Therapeutics by 24.4% during the first quarter. Wells Fargo & Company MN now owns 84,710 shares of the biotechnology company’s stock valued at $2,508,000 after acquiring an additional 16,620 shares in the last quarter. Princeton Alpha Management LP purchased a new position in Sarepta Therapeutics during the first quarter valued at $270,000. Bank of New York Mellon Corp grew its stake in Sarepta Therapeutics by 0.8% during the first quarter. Bank of New York Mellon Corp now owns 247,924 shares of the biotechnology company’s stock valued at $7,339,000 after acquiring an additional 1,923 shares in the last quarter. Finally, Pictet Asset Management Ltd. grew its stake in Sarepta Therapeutics by 24.7% during the first quarter. Pictet Asset Management Ltd. now owns 67,600 shares of the biotechnology company’s stock valued at $2,001,000 after acquiring an additional 13,400 shares in the last quarter. 65.43% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.